BioVie Inc., a clinical-stage company focused on developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease, has released its financial results for the fiscal year ending June 30, 2025. The company reported a net loss of approximately $17.5 million and net cash used in operating activities amounting to $19.0 million for the year. To date, BioVie Inc. has not generated any revenues, and no revenues are anticipated in the foreseeable future. The company emphasized the importance of securing additional capital to sustain its operations, with potential future funding sources including sales of equity, obtaining loans, or engaging in other strategic transactions. However, there is significant uncertainty regarding the company's ability to acquire sufficient financing on acceptable terms, which raises substantial doubt about its ability to continue as a going concern. BioVie Inc. continues to pursue its strategic plans, focusing on the development and commercialization of its drug therapies.